Education
About Us
Working with TipRanks
Follow Us
Metagenomi, Inc. (MGX)
NASDAQ:MGX
MGX Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MGX Stock 12 Month Forecast
Average Price Target
$7.00
▲(274.33% Upside)
| Highest Price Target$7.00 | Average Price Target$7.00 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$2
Hold
6.95%
Upside
Reiterated
08/26/25
H.C. Wainwright
$7
Buy
274.33%
Upside
Reiterated
08/19/25
TD Cowen
―
Buy
―
Reiterated
08/12/25
Metagenomi, Inc. (MGX) Gets a Buy from TD CowenWe see long-term value as the platform progresses. IND Hemophilia A 2026 MGX noted today that the company remains on track to engage with regulators around its hemophilia A gene editing program in H2:25. Recall, Metagenomi announced long-term FVIII durability data from its hemophilia A program last quarter, which demonstrated that all three treated NHPs had sustained FVIII activity, with two in mild hemophilia range (6-40% of normal) and a third in the normal range (50-150%) as of the last update in the study. Each NHP had sustained mean plasma FVIII activity over time (75%, 8%, and 29% across months 12-19 compared to 75%, 9%, and 29% across months 3-6) and FVIII activity levels correlated with gene integration frequency of (5.3%, 0.89%, 2.5%) in liver biopsies at termination of the study.
Wells Fargo
$20→$16
Buy
755.61%
Upside
Reiterated
05/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$2
Hold
6.95%
Upside
Reiterated
08/26/25
H.C. Wainwright
$7
Buy
274.33%
Upside
Reiterated
08/19/25
TD Cowen
―
Buy
―
Reiterated
08/12/25
Metagenomi, Inc. (MGX) Gets a Buy from TD CowenWe see long-term value as the platform progresses. IND Hemophilia A 2026 MGX noted today that the company remains on track to engage with regulators around its hemophilia A gene editing program in H2:25. Recall, Metagenomi announced long-term FVIII durability data from its hemophilia A program last quarter, which demonstrated that all three treated NHPs had sustained FVIII activity, with two in mild hemophilia range (6-40% of normal) and a third in the normal range (50-150%) as of the last update in the study. Each NHP had sustained mean plasma FVIII activity over time (75%, 8%, and 29% across months 12-19 compared to 75%, 9%, and 29% across months 3-6) and FVIII activity levels correlated with gene integration frequency of (5.3%, 0.89%, 2.5%) in liver biopsies at termination of the study.
Wells Fargo
$20→$16
Buy
755.61%
Upside
Reiterated
05/14/25
Best Analysts Covering Metagenomi, Inc.
1 Month
xxx
Success Rate
4/10 ratings generated profit
Average Return
+3.03%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +3.03% per trade.
3 Months
xxx
Success Rate
5/10 ratings generated profit
Average Return
-8.12%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -8.12% per trade.
1 Year
Success Rate
4/8 ratings generated profit
Average Return
-23.59%
reiterated a buy rating 17 days ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -23.59% per trade.
2 Years
xxx
Success Rate
4/8 ratings generated profit
Average Return
-22.81%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -22.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MGX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
6
5
4
1
Buy
2
2
1
1
1
Hold
2
6
7
15
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
14
13
20
16
Each month's total comprises the sum of three months' worth of ratings.
MGX Financial Forecast
MGX Stock Forecast FAQ
What is MGX’s average 12-month price target, according to analysts?
Based on analyst ratings, Metagenomi, Inc.’s 12-month average price target is 7.00.
What is MGX’s upside potential, based on the analysts’ average price target?
Metagenomi, Inc. has 274.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MGX a Buy, Sell or Hold?
Metagenomi, Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Metagenomi, Inc.’s price target?
The average price target for Metagenomi, Inc. is 7.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 274.33% Increase from the current price of $1.87.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 274.33% Increase from the current price of $1.87.
What do analysts say about Metagenomi, Inc.?
Metagenomi, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of MGX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.